1,4-bis(2-(3,5-dichloropyridyloxy))benzene has been researched along with methotrexate in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Halwachs, S; Honscha, W; Schaefer, I; Seibel, P | 1 |
2 other study(ies) available for 1,4-bis(2-(3,5-dichloropyridyloxy))benzene and methotrexate
Article | Year |
---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Antiepileptic drugs reduce the efficacy of methotrexate chemotherapy through accelerated degradation of the reduced folate carrier by the ubiquitin-proteasome pathway.
Topics: Animals; Anticonvulsants; Antimetabolites, Antineoplastic; Biosynthetic Pathways; Cell Line; Constitutive Androstane Receptor; Cytochrome P-450 Enzyme System; Drug Interactions; Half-Life; Methotrexate; Phenobarbital; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase C; Pyridines; Rats; Receptors, Cytoplasmic and Nuclear; Reduced Folate Carrier Protein; Replication Protein C; Repressor Proteins; Ubiquitin | 2011 |